The company's biotechnology platform focuses on developing treatments for immune diseases and transplantation therapies. Their products, such as TM-400 for HSCT, have the potential to cure patients with hematological cancers like multiple melanomas and non-Hodgkin lymphoma. Additionally, TikoMed aims to improve the outcome of regenerative stem-cell therapy, providing hope for patients with severe diabetes by improving the outcome of transplantation of insulin-producing beta cells.